Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

This real-world observational study is examining how a combination of two antipsychotic medications — Abilify Maintena (aripiprazole, a once-monthly injection) and Rexulti (brexpiprazole, a daily pill) — works in people with schizophrenia and related conditions in everyday clinical settings in Singapore and Hong Kong. **You may be eligible if...** - You are 18–65 years old - You have been diagnosed with schizophrenia, schizoaffective disorder, schizotypal disorder, delusional disorder, schizophreniform disorder, or a brief psychotic disorder - You are currently receiving both Abilify Maintena and brexpiprazole together as treatment, and have been on this combination for 8 weeks or less at enrollment - You can read and communicate in English and/or Chinese **You may NOT be eligible if...** - You are under 18 years old - You are unable to read English or Chinese - You have an intellectual disability - You cannot give informed consent Talk to your doctor to see if this trial is right for you.